Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors

Molecular Therapy

Volumn 17, Issue 2, 2009, Pages 373-379

  Liu, Te Hui ^a   Oscherwitz, Jon ^b   Schnepp, Bruce ^a   Jacobs, Jana ^b   Yu, Fen ^b   Cease, Kemp B ^b,c   Johnson, Philip R ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; BACTERIAL ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR; PROTECTIVE ANTIGEN 63; UNCLASSIFIED DRUG; ANTHRAX VACCINE; BACTERIAL TOXIN; GREEN FLUORESCENT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTHRAX; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNOGENICITY; LETHAL GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; RABBIT; SINGLE DRUG DOSE; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; VIRUS NEUTRALIZATION; WESTERN BLOTTING; ADENO ASSOCIATED VIRUS; ANIMAL; CYTOMEGALOVIRUS; GENE VECTOR; GENETICS; HELA CELL; IMMUNOLOGY; METABOLISM; PROMOTER REGION;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS - 1; BACILLUS ANTHRACIS; HUMAN HERPESVIRUS 5; ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTHRAX VACCINES; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BLOTTING, WESTERN; CYTOMEGALOVIRUS; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; PROMOTER REGIONS, GENETIC; RABBITS;

EID: 63649105706     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.242     Document Type: Article

References (50)

1. Hudson, MJ, Beyer, W, Bohm, R, Fasanella, A, Garofolo, G, Golinski, R et al. (2008). Bacillus anthracis: Balancing innocent research with dual-use potential. Int J Med Microbiol 298: 345-364.
2. Collier, RJ and Young, JA (2003). Anthrax toxin. Annu Rev Cell Dev Biol 19: 45-70.
3. Moayeri, M and Leppla, SH (2004). The roles of anthrax toxin in pathogenesis. Curr Opin Microbiol 7: 19-24.
4. Dixon, TC, Meselson, M, Guillemin, J and Hanna, PC (1999). Anthrax. N Engl J Med 341: 815-826.
5. Turnbull, PC, Leppla, SH, Broster, MG, Quinn, CP and Melling, J (1988). Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol 177: 293-303.
6. Pezard, C, Weber, M, Sirard, JC, Berche, P and Mock, M (1995). Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect Immun 63: 1369-1372.
7. Price, BM, Liner, AL, Park, S, Leppla, SH, Mateczun, A and Galloway, DR (2001). Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 69: 4509-4515.
8. Taft, SC and Weiss, AA (2007). Role of vaccine-induced antibodies to anthrax lethal and edema toxin. Clin Vaccine Immunol 15: 71-75.
9. Sherer, K, Li, Y, Cui, X and Eichacker, PQ (2007). Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy. Am J Respir Crit Care Med 175: 211-221.
10. Cui, X, Li, Y, Li, X, Laird, MW, Subramanian, M, Moayeri, M et al. (2007). Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis 195: 572-580.
11. Puziss, M and Wright, GG (1963). Studies on immunity in anthrax. X Gel-adsorbed protective antigen for immunization of man. J Bacteriol 85: 230-236.
12. Ivins, BE, Pitt, ML, Fellows, PF, Farchaus, JW, Benner, GE, Waag, DM et al. (1998). Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16: 1141-1148.
13. Pitt, ML, Little, SF, Ivins, BE, Fellows, P, Barth, J, Hewetson, J et al. (2001). In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19: 4768-4773.
14. Fellows, PF, Linscott, MK, Ivins, BE, Pitt, ML, Rossi, CA, Gibbs, PH et al. (2001). Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19: 3241-3247.
15. Brachman, PS, Gold, H, Plotkin, SA, Fekety, FR, Werrin, M and Ingraham, NR (1962). Field evaluation of a human anthrax vaccine. Am J Public Health Nations Health 52: 632-645.
16. FDA (2005). Biological products; bacterial vaccines and toxoids; implementation of efficacy review; anthrax vaccine adsorbed; final order. Fed Regist 70: 75180-75198.
17. Demicheli, V, Rivetti, D, Deeks, JJ, Jefferson, T and Pratt, M (1998). The effectiveness and safety of vaccines against human anthrax: A systematic review. Vaccine 16: 880-884.
18. Sever, JL, Brenner, AI, Gale, AD, Lyle, JM, Moulton, LH and West, DJ (2002). Safety of anthrax vaccine: A review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol Drug Saf 11: 189-202.
19. Pittman, PR, Kim-Ahn, G, Pifat, DY, Coonan, K, Gibbs, P, Little, S et al. (2002). Anthrax vaccine: Immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20: 1412-1420.
20. Joellenbeck, JM, Zwanziger, LL, Durch, JS and Strom, BL, eds. (2002). The Anthrax Vaccine: Is it safe? Does it work? National Academies Press: Washington, DC.
21. Grimm, D and Kay, MA (2003). From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 3: 281-304.
22. Tenenbaum, L, Lehtonen, E and Monahan, PE (2003). Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther 3: 545-565.
23. Coura Rdos, S and Nardi, NB (2007). The state of the art of adeno-associated virus-based vectors in gene therapy. Virol J 4 99.
24. Manning, WC, Paliard, X, Zhou, S, Pat Bland, M, Lee, AY, Hong, K et al. (1997). Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J Virol 71: 7960-7962.
25. Liu, X, Voulgaropoulou, F, Chen, R, Johnson, PR and Clark, KR (2000). Selective Rep- Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol Ther 2 394-403.
26. Johnson, PR, Schnepp, BC, Connell, MJ, Rohne, D, Robinson, S, Krivulka, GR et al. (2005). Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 79: 955-965.
27. Kuck, D, Lau, T, Leuchs, B, Kern, A, Muller, M, Gissmann, L et al. (2006). Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol 80: 2621-2630.
28. Palmiter, RD, Sandgren, EP, Avarbock, MR, Allen, DD and Brinster, RL (1991). Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci USA 88: 478-482.
29. Lacy, DB, Mourez, M, Fouassier, A and Collier, RJ (2002). Mapping the anthrax protective antigen binding site on the lethal and edema factors. J Biol Chem 277: 3006-3010.
30. Ferrari, FK, Samulski, T, Shenk, T and Samulski, RJ (1996). Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 70: 3227-3234.
31. Brockstedt, DG, Podsakoff, GM, Fong, L, Kurtzman, G, Mueller-Ruchholtz, W and Engleman, EG (1999). Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 92: 67-75.
32. Xin, KQ, Urabe, M, Yang, J, Nomiyama, K, Mizukami, H, Hamajima, K et al. (2001). A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum Gene Ther 12: 1047-1061.
33. Xin, KQ, Ooki, T, Mizukami, H, Hamajima, K, Okudela, K, Hashimoto, K et al. (2002). Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum Gene Ther 13: 1571-1581.
34. Xin, KQ, Mizukami, H, Urabe, M, Toda, Y, Shinoda, K, Yoshida, A et al. (2006). Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J Virol 80 11899-11910.
35. Logan, GJ, Wang, L, Zheng, M, Cunningham, SC, Coppel, RL and Alexander, IE (2007). AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection. Vaccine 25: 1014-1022.
36. Mueller, C and Flotte, TR (2008). Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 15: 858-863.
37. Du, L, Zhao, G, Lin, Y, Sui, H, Chan, C, Ma, S et al. (2008). Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol 180: 948-956.
38. Gallez-Hawkins, G, Li, X, Franck, AE, Thao, L, Lacey, SF, Diamond, DJ et al. (2004). DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice. Vaccine 23: 819-826.
39. Little, SF, Ivins, BE, Fellows, PF and Friedlander, AM (1997). Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 65: 5171-5175.
40. Pitt, ML, Little, S, Ivins, BE, Fellows, P, Boles, J, Barth, J et al. (1999). In vitro correlate of immunity in an animal model of inhalational anthrax. J Appl Microbiol 87: 304.
41. Hermanson, G, Whitlow, V, Parker, S, Tonsky, K, Rusalov, D, Ferrari, M et al. (2004). A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA 101: 13601-13606.
42. Xu, Q and Zeng, M (2008). Detoxified lethal toxin as a potential mucosal vaccine against anthrax. Clin Vaccine Immunol 15: 612-616.
43. Gu, ML, Leppla, SH and Klinman, DM (1999). Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine 17: 340-344.
44. Galloway, D, Liner, A, Legutki, J, Mateczun, A, Barnewall, R and Estep, J (2004). Genetic immunization against anthrax. Vaccine 22: 1604-1608.
45. Clark, KR, Voulgaropoulou, F and Johnson, PR (1996). A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther 3: 1124-1132.
46. Clark, KR, Voulgaropoulou, F, Fraley, DM and Johnson, PR (1995). Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther 6: 1329-1341.
47. Rabinowitz, JE, Rolling, F, Li, C, Conrath, H, Xiao, W, Xiao, X et al. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76: 791-801.
48. Clark, KR, Liu, X, McGrath, JP and Johnson, PR (1999). Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther 10: 1031-1039.
49. Schnepp, BC, Clark, KR, Klemanski, DL, Pacak, CA and Johnson, PR (2003). Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 77: 3495-3504.
50. Oscherwitz, J, Hankenson, FC, Yu, F and Cease, KB (2006). Low-dose intraperitoneal Freund's adjuvant: Toxicity and immunogenicity in mice using an immunogen targeting amyloid-beta peptide. Vaccine 24 3018-3025.